ScinoPharm Taiwan Statistics

Total Valuation

ScinoPharm Taiwan has a market cap or net worth of TWD 19.49 billion. The enterprise value is 15.94 billion.

Market Cap	19.49B
Enterprise Value	15.94B

Important Dates

The next estimated earnings date is Tuesday, November 5, 2024.

Earnings Date	Nov 5, 2024
Ex-Dividend Date	Jul 4, 2024

Share Statistics

ScinoPharm Taiwan has 790.74 million shares outstanding. The number of shares has increased by 0.01% in one year.

Shares Outstanding	790.74M
Shares Change (YoY)	+0.01%
Shares Change (QoQ)	+0.01%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	3.35%
Float	247.21M

Valuation Ratios

The trailing PE ratio is 49.31.

PE Ratio	49.31
Forward PE	n/a
PS Ratio	5.69
PB Ratio	1.88
P/FCF Ratio	57.34
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.44, with an EV/FCF ratio of 46.89.

EV / Earnings	39.55
EV / Sales	4.65
EV / EBITDA	17.44
EV / EBIT	36.05
EV / FCF	46.89

Financial Position

The company has a current ratio of 6.86, with a Debt / Equity ratio of 6.29.

Current Ratio	6.86
Quick Ratio	4.83
Debt / Equity	6.29
Debt / EBITDA	0.71
Debt / FCF	1.92
Interest Coverage	52.61

Financial Efficiency

Return on equity (ROE) is 3.92% and return on invested capital (ROIC) is 2.53%.

Return on Equity (ROE)	3.92%
Return on Assets (ROA)	2.31%
Return on Capital (ROIC)	2.53%
Revenue Per Employee	6.35M
Profits Per Employee	746,300
Employee Count	540
Asset Turnover	0.29
Inventory Turnover	1.27

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -8.21% in the last 52 weeks. The beta is 0.33, so ScinoPharm Taiwan's price volatility has been lower than the market average.

Beta (5Y)	0.33
52-Week Price Change	-8.21%
50-Day Moving Average	25.56
200-Day Moving Average	26.66
Relative Strength Index (RSI)	43.30
Average Volume (20 Days)	466,223

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ScinoPharm Taiwan had revenue of TWD 3.43 billion and earned 403.00 million in profits. Earnings per share was 0.50.

Revenue	3.43B
Gross Profit	1.33B
Operating Income	442.06M
Pretax Income	495.31M
Net Income	403.00M
EBITDA	897.12M
EBIT	442.06M
Earnings Per Share (EPS)	0.50

Full Income Statement

Balance Sheet

The company has 4.21 billion in cash and 652.41 million in debt, giving a net cash position of 3.55 billion or 4.50 per share.

Cash & Cash Equivalents	4.21B
Total Debt	652.41M
Net Cash	3.55B
Net Cash Per Share	4.50
Equity (Book Value)	10.37B
Book Value Per Share	13.12
Working Capital	5.70B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 604.29 million and capital expenditures -264.37 million, giving a free cash flow of 339.92 million.

Operating Cash Flow	604.29M
Capital Expenditures	-264.37M
Free Cash Flow	339.92M
FCF Per Share	0.43

Full Cash Flow Statement

Margins

Gross margin is 38.89%, with operating and profit margins of 12.89% and 11.76%.

Gross Margin	38.89%
Operating Margin	12.89%
Pretax Margin	14.45%
Profit Margin	11.76%
EBITDA Margin	26.17%
EBIT Margin	12.89%
FCF Margin	9.92%

Dividends & Yields

This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 1.24%.

Dividend Per Share	0.30
Dividend Yield	1.24%
Dividend Growth (YoY)	-16.67%
Years of Dividend Growth	n/a
Payout Ratio	70.64%
Buyback Yield	-0.01%
Shareholder Yield	1.23%
Earnings Yield	2.03%
FCF Yield	1.74%

Dividend Details

Stock Splits

The last stock split was on August 10, 2017. It was a forward split with a ratio of 1.04.

Last Split Date	Aug 10, 2017
Split Type	Forward
Split Ratio	1.04